NDAORALFOR SUSPENSION
Approved
Feb 2013
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Clinical Trials
7
Data completeness
5/8 — Partial
SUPRAX (cefixime) by Inpharmus is [see microbiology ( )] . Approved for typhoid fever, gonorrhea, bacterial vaginitis and 1 more indications. First approved in 2013.
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SUPRAX (cefixime) is an oral third-generation cephalosporin antibiotic approved in 2013 for treatment of typhoid fever, gonorrhea, bacterial vaginitis, and cervicitis. It works by inhibiting bacterial cell wall synthesis through beta-lactam mechanism. The suspension formulation enables dosing in pediatric and adult populations requiring oral therapy.
LOE Approaching2.6 years to LOE
Product approaching loss of exclusivity with 2.7 years of patent protection remaining; commercial teams likely in defensive or transition planning mode.
Mechanism of Action
[see Microbiology ( )] .
Indications (4)
Worked on SUPRAX at Inpharmus? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.